# An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

> **NCT06015464** · — · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 81 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type

## Interventions

- **DRUG:** Orelabrutinib

## Key facts

- **NCT ID:** NCT06015464
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015464, "An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06015464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*